This Week’s Top Stories in Biotech
Most Popular - Jason Napodano laid out the DRRX investment thesis. Will Pfizer re-file the Remoxy NDA? And what about Posidur? They’re both real value drivers for DRRX, … Continue Reading
Read nowSearch Results for questcor
PropThink’s Lead Stories in Biotech
Long Ideas - On Friday, PropThink launched its database of Special Protocol Assessments, or SPAs. These trials are, in essence, a FDA-blessed measure to mitigate clinical efficacy risk … Continue Reading
Read nowFundamentals and Technicals Continue to Support QCOR
Long Ideas - Shares of Questcor Pharmaceuticals (NASDAQ:QCOR), despite a large short interest, have continued to perform well for shareholders and broke through several resistance levels this week to … Continue Reading
Read now‘Trouble Is Opportunity’; Endo Fallout is Worth A Look
Long Ideas - It’s not easy to do, but buying when there’s blood in the streets is a way many have scored big on Wall Street. Take our … Continue Reading
Read nowA Recap of PropThink’s Top Stories this Week
Most Popular - Amarin plans to “go it alone” with its Vascepa launch. Without a large pharma partnership or, better yet, an acquirer, we don’t expect investors to … Continue Reading
Read nowQCOR Shorts Running Out Of Material; Stock Set to Run
Long Ideas - The price action in shares of Questcor Pharmaceuticals (QCOR) Thursday was telling, with a quick reaction to a negative article published on the company, followed … Continue Reading
Read nowQCOR Accelerated Dividend Highlights Acthar Growth
Long Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR) announced a per share cash dividend of $0.20 to shareholders of record on December 14, 2012. The payment is accelerated, as the … Continue Reading
Read now